Clinical Trial News
Congratulations to our Dr. Crawford whose article “Narrowing the Diversity Gap” in Clinical Trials launched today in USA Today and on Future of Personal Health!
September 13th, 2024 | Clinical Trial NewsPHEN Survivor Network Member Art Cain Beats Prostate Cancer with PANTHER Trial After Attending PHEN Summit
July 22nd, 2024 | Clinical Trial News
Black men are 70% more likely to become diagnosed with prostate cancer as all other men and more than twice as likely to die from this disease. However, diverse patient enrollment in prostate cancer clinical trials may make a difference in reducing this racial disparity. PHEN Survivor Network Member Art Cain is one such man […]
How PHEN’s Clinical Trials Navigation Hotline Can Help You
April 2nd, 2024 | Clinical Trial News
How can clinical researchers and pharmaceutical companies increase the diversity of their clinical trial subjects?
December 21st, 2023 | Clinical Trial News
PHEN Hosts Successful Clinical Trials Learning Session with MSKCC
December 11th, 2023 | Clinical Trial News
PHEN to Raise Prostate Cancer Awareness at the Cotton Bowl in Dallas, TX During the Annual State Fair Classic on September 30th
December 11th, 2023 | Clinical Trial News
A New Era in Prostate Cancer Treatment: Embracing Second-Generation Antiandrogens
December 11th, 2023 | Clinical Trial News
PHEN participated in FDA’s Black Family Cancer Awareness Week
December 11th, 2023 | Clinical Trial News
Epigenetics: A New Hope in Fighting Prostate Cancer
December 11th, 2023 | Clinical Trial News
PHEN Supports Talapro-3 Clinical Trial
December 11th, 2023 | Clinical Trial News
PHEN’s Clinical Trials Rally’s approach of educating Black prostate cancer patients about clinical trials, as well as strategic partnerships with pharmaceutical companies to amplify this message, is contributing to greater diversity among clinical trial participants. In addition to Pfizer’s TALAPRO-2 clinical trial featured in FDA approved post, PHEN also supported its TALAPRO-3 trial. Pfizer reported that they […]
